The long-term impact of sustained exposure-reducing interventions (represented by a decrease in density of female anophelines). by Azra C. Ghani (160248)

Mean platelet volume and neutrophil to lymphocyte ratio decrease in patients with depression with antidepressant treatment by AHMET ÖZTÜRK (8077292)

Decreased Tks5 expression results in neural crest-derived defects. by Danielle A. Murphy (212554)

“…(C) Melanophores present in the dorsal, ventral, and lateral pigment lines were quantified to determine degree of murine Tks5 rescue of the decreased pigmentation seen in morphants. …”

LPS dose-dependently decreases T cell proliferative response to OKT3. by Fanny Poujol (834338)

Inhibition of ATR activation significantly decreases B19V-induced G2 arrest in infected CD36⁺ EPCs. by Peng Xu (17962)

MBCD decreased stemness in MDA-MB-231. by Ankit Sharma (578833)

“…After 24 hr, cells were treated with MBCD (1mM). After 5 days, formed colonies were stained with crystal violet. …”

Tom clone number and area decrease during pupariation. by Jeremy Brown (3311742)

Monocytes mediate LPS induced decrease of T cell proliferative response to OKT3. by Fanny Poujol (834338)

Means and Cronbach’s alphas for 5C and VAX-measured vaccination attitudes over 12 months. by Allyson J. Gallant (9382396)

Subjects:

The decrease in lactate induced by pyruvate is blocked by inhibition of MAS and of the TCA cycle in HKI/HKII double KD cells. by Scott John (228011)

“…Phase 2a2 evoked by pyruvate had a mean amplitude of 27.97±1.41 (n = 61). With the addition of NaCN phase 4a2 had a mean amplitude of 19.6±1.63 (n = 61). …”

Here we speculate on the possible interactions between cell autonomous circadian and somite oscillator components during somite formation and differentiation. by Kristen L. Curran (95520)

Crude and adjusted analysis of the incidence of decreased glomerular filtration over the 6-year study period, considering Model 1 and Model 2. by Camila de Souza dos Santos (17721066)

Cronbach’s alpha and means the stigma of Suicide Scale Short Form (SOSS-SF). by Orrin D. Ware (14829115)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects: